COVID-END partners coordination call
Agenda for 6 May 2021
https://zoom.us/j/6163788736

1. INTRODUCTIONS
   a. Jeremy welcomed Jenn Verma to introduce the Global Commission on Evidence to Address Societal Challenges

2. REVIEW OF COVID-END ACTION ITEMS
   a. Jeremy pointed partners to the partner notes from 15 April (see attachment 2)

3. COVID-END NETWORK UPDATES
   a. Jeremy introduced variants of concern as a thematic area of focus and introduced two COVID-END members to speak about their work
      i. Janet Curran described her evidence synthesis on transmission characteristics (transmission characteristics of SARS-CoV-2 variants of concern) and the living evidence table being maintained by the Agency for Clinical Innovation in New South Wales (https://aci.health.nsw.gov.au/covid-19/critical-intelligence-unit/sars-cov-2-variants), as well as the first edition of her living evidence synthesis on public health and health systems impacts of SARS-CoV-2 variants of concern
      ii. Alfonso Iorio introduced his living evidence synthesis on vaccine effectiveness against variants, which is updated every Friday: What is the efficacy and effectiveness of available COVID-19 vaccines in general and specifically for variants of concern?
   b. Jeremy provided an update on WHO-ECC 19 paper and indicated that he’d get back to the group about authorship criteria
   c. Maureen provided an update about progress with citizen partnership
   d. Jenn Verma gave a brief presentation about the Global Commission on Evidence to Address Societal Challenges

4. PARTNER PROFILE
   a. Michael McCaul and Tamara Kredo highlighted their contributions to COVID-19 response at both:
      i. Centre for Evidence-based Health Care, Stellenbosch University
      ii. South African Medical Research Council and Cochrane Africa

5. NEWS AND INITIATIVES OF INTEREST TO PARTNERS
   a. Jeremy pointed partners to Evidence Synthesis Ireland’s Priority III study
      i. Online survey asking patient and public representatives, reviewers, researchers, clinicians and policymakers to select the 10 questions that are most important for future research to address
ii. Survey can be found [here](#).
b. Jeremy also pointed partners to Evidence Aid’s April update for COVID-19 project
   i. Prepared more than 500 short, plain language summaries covering almost 800 systematic reviews relevant to the COVID-19 pandemic and its impact
   ii. Summaries are available in English, with translations into other languages including Arabic, Chinese, French, German, Italian, Portuguese and Spanish
       Summaries are freely accessible [here](#) along with links to the full reviews

### 6. ANY OTHER BUSINESS

a. No other business